금융 뉴스 허브

‘I Don’t Trust Anybody Guaranteeing to Double My Money’: Ramsey Show Host to Couple Weeks From Retirement

A couple weeks from retirement, a Rochester woman handed an advisor her seven-figure nest egg and walked away with a promise that set off alarm bells on national radio. What the pitch left out could h ...

Rivian vs. the S&P 500: Which Investment Wins Through 2030?

The electric vehicle maker looks undervalued, but it has a lot to prove.

The S&P 500’s newest tech stock is now its best performer

Shares of data-storage company Everpure were leading S&P 500 gainers on Thursday.

An 8-Day Losing Streak Has Charter Communications Stock Down 20%

Charter Communications (CHTR) stock has now moved lower for 8 consecutive trading days, a cumulative loss of 20%. That streak has erased about $3.5 billion from the company's market value, which now s ...

SCHD Is Down From Its All-Time High. Here's Why I'm Not Selling.

Modest pullbacks are normal and shouldn't alter long-term investment strategies.

3 Reasons to Sell EXPD and 1 Stock to Buy Instead

Expeditors’s 32.6% return over the past six months has outpaced the S&P 500 by 14.2%, and its stock price has climbed to $188.25 per share. This was partly thanks to its solid quarterly results, and t ...

U.S. 10-year Treasury surpasses 5.15%, but it's the speed that's becoming the story

Google unveils new Gemini 3.8 Live with Live Avatar model

Blackstone launches BXPM fund to simplify access to private markets

3 Reasons HLMN is Risky and 1 Stock to Buy Instead

Over the last six months, Hillman’s shares have sunk to $7.31, producing a disappointing 12.7% loss - a stark contrast to the S&P 500’s 18.4% gain. This might have investors contemplating their next m ...

Why Google and SpaceX Are Testing AI in Orbit: The Earthly Grid Can’t Keep Up.

Google’s test launch with SpaceX will evaluate how its Tensor Processing Unit chips perform in space.

XLV vs IBB: How Healthcare Diversification Compares to Biotech Concentration

XLV offers exposure to the broader healthcare sector, while IBB targets biotech innovators. Here's how the two stack up on risk, returns, and diversification.